<SUBMISSION>
<ACCESSION-NUMBER>0000920148-00-000041
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>2
<PERIOD>20000713
<ITEMS>5
<ITEMS>7
<FILING-DATE>20000725
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>LABORATORY CORP OF AMERICA HOLDINGS
<CIK>0000920148
<ASSIGNED-SIC>8071
<IRS-NUMBER>133757370
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>001-11353
<FILM-NUMBER>678497
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>358 S MAIN ST
<CITY>BURLINGTON
<STATE>NC
<ZIP>27215
<PHONE>3362291127
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>358 S MAIN ST
<STREET2>4225 EXECUTIVE SQUARE, SUITE 800
<CITY>BURLINGTON
<STATE>NC
<ZIP>27215
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>NATIONAL HEALTH LABORATORIES HOLDINGS INC
<DATE-CHANGED>19940314
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>0001.txt
<TEXT>




      UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                   WASHINGTON, D.C. 20549

                          FORM 8-K

                       CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
                        JULY 13, 2000
                     ------------------
              (Date of earliest event reported)


         LABORATORY CORPORATION OF AMERICA HOLDINGS
         ------------------------------------------
   (Exact name of registrant as specified in its charter)


   DELAWARE                1-11353             13-3757370
 --------------          -----------         --------------
(State or other         (Commission         (IRS Employer
jurisdiction of         File Number)         Identification
incorporation)                                    Number)


   358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA 27215
   -------------------------------------------------------
          (Address of principal executive offices)

                        336-229-1127
                        ------------
    (Registrant's telephone number, including area code)


<PAGE>

ITEM 5. OTHER EVENTS

  On  July  13,  2000,  Laboratory Corporation  of  America-
Registered Trademark- Holdings (LabCorp-Registered Trademark-
)  announced that more than 99.97 percent of the  shares  of
its   outstanding  8  1/2  percent  Series   A   Convertible
Exchangeable  Preferred Stock and 8  1/2  percent  Series  B
Convertible   Pay-in-Kind   Preferred   Stock   called   for
redemption  have  been converted into the  Company's  common
stock   at   the  request  of  the  preferred  shareholders.
Conversion  of  such shares of preferred stock  into  common
stock  has  resulted  in the issuance of approximately  20.9
million   additional  shares  of  common  stock  since   the
redemption  was announced on June 6, 2000, for  a  total  of
approxomately 34.3 million common shares outstanding.


ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL
        INFORMATION AND EXHIBITS

 (c)  Exhibit
      20  Press release of the Company dated
          July 13, 2000.

<PAGE>

                         SIGNATURES

Pursuant to the requirements of the Securities and Exchange
Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.

          LABORATORY CORPORATION OF AMERICA HOLDINGS
          ------------------------------------------
                         (Registrant)

               By:/S/ BRADFORD T. SMITH
                  ------------------------------
                      Bradford T. Smith
                      Executive Vice President,
                      General Counsel, Secretary
                      and Compliance Officer



Date: July 21, 2000

<PAGE>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-20
<SEQUENCE>2
<FILENAME>0002.txt
<TEXT>



Laboratory Corporation of America-Registered Trademark- Holdings
358 South Main Street
Burlington, NC   27215
Telephone:  336-584-5171

FOR IMMEDIATE RELEASE
---------------------
Contact:  336-436-4855                  Shareholder Direct: 800-LAB-0401
          Pamela Sherry                                     www.labcorp.com



 LABORATORY CORPORATION OF AMERICA-REGISTERED TRADEMARK- SUCCESSFULLY
                COMPLETES PREFERRED STOCK REDEMPTION

       99.97 Percent of Preferred Shares Converted into Common

Burlington, NC, July 13, 2000 - Laboratory Corporation of America-
Registered Trademark- Holdings (LabCorp-Registered Trademark- NYSE:
LH) today announced that more than 99.97 percent of the shares of its
outstanding 8 1/2 percent Series A Convertible Exchangeable Preferred
Stock and 8 1/2 percent Series B Convertible Pay-in-Kind Preferred
Stock called for redemption have been converted into the Company's
common stock at the request of the preferred shareholders. Conversion
of such shares of preferred stock into common stock has resulted in
the issuance of approximately 20.9 million additional shares of
common stock since the redemption was announced on June 6, 2000, for
a total of approximately 34.3 million common shares outstanding.

"Our preferred shareholders have validated their confidence in
LabCorp and our business model by electing to convert essentially 100
percent of their preferred shares into LabCorp common stock," said
Thomas P. Mac Mahon, chairman and chief executive officer.  "We are
pleased that our ongoing efforts to build shareholder value have
created a new, simplified capital structure for the benefit of our
common shareholders."

Laboratory Corporation of America-Registered Trademark- Holdings
(LabCorp-Registered Trademark-) is a national clinical laboratory
with annual revenues of $1.7 billion in 1999.  With 18,000 employees
and over 100,000 clients nationwide, the Company offers more than
2,000 clinical tests ranging from simple blood analyses to
sophisticated molecular diagnostics. LabCorp leverages its expertise
in innovative clinical testing technology with three Centers of
Excellence. The Center for Molecular Biology and Pathology, in
Research Triangle Park (RTP), North Carolina, develops applications
for polymerase chain reaction (PCR) technology. Its Center for

<PAGE>
Occupational Testing in RTP is the world's largest substance abuse
testing facility, and the Center for Esoteric Testing in Burlington,
North Carolina, performs the largest volume of specialty testing in
the network.  LabCorp's clients include physicians, state and federal
government, managed care organizations, hospitals, clinics,
pharmaceutical and Fortune 1000 companies, and other clinical
laboratories.

Each of the above forward-looking statements is subject to change
based on various important factors, including without limitation,
competitive actions in the marketplace and adverse actions of
governmental and other third-party payors.  Further information on
potential factors that could affect LabCorp's financial results is
included in the Company's Form 10-K for the year ended December 31,
1999 and subsequent SEC filings.

                                 ###
_______________________________

</TEXT>
</DOCUMENT>
</SUBMISSION>
